1 – 10 of 13
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Analytical performance of aPROMISE : automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting
(
- Contribution to journal › Article
-
Mark
Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate Cancer
(
- Contribution to journal › Article
- 2020
-
Mark
Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy
2020) In Proceedings of the National Academy of Sciences of the United States of America 117(26). p.15172-15181(
- Contribution to journal › Article
- 2018
-
Mark
Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer a secondary analysis of a randomized clinical trial
(
- Contribution to journal › Article
- 2016
-
Mark
Analytical Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize the Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.
(
- Contribution to journal › Article
-
Mark
A preanalytic validation study of automated bone scan index : Effect on accuracy and reproducibility due to the procedural variabilities in bone scan image acquisition
(
- Contribution to journal › Article
-
Mark
Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide.
(
- Contribution to journal › Article
- 2015
-
Mark
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
(
- Contribution to journal › Article
- 2014
-
Mark
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
(
- Contribution to journal › Article
-
Mark
Wound management
(
- Contribution to journal › Article